Parallel Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Parallel Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.11K	Hold	100	–	–	﹤0.01%	3521
2025 Q4	$1.66K	Sell	100 -86	-46%	-$1.23K	﹤0.01%	3180
2025 Q3	$2.19K	Hold	186	–	–	﹤0.01%	3022
2025 Q2	$1.78K	Sell	186 -143	-43%	-$791	﹤0.01%	3066
2025 Q1	$2.06K	Buy	+329	New	+$2K	﹤0.01%	2969
2023 Q1	–	Sell	-29	Closed	-$325	–	3482
2022 Q4	$325	Hold	29	–	–	﹤0.01%	3115
2022 Q3	$0	Buy	+29	New	+$276	﹤0.01%	3408
2022 Q2	–	Sell	-80	Closed	-$1K	–	3265
2022 Q1	$1K	Buy	80 +8	+11%	+$129	﹤0.01%	2808
2021 Q4	$1K	Buy	+72	New	+$1.69K	﹤0.01%	2932

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Parallel Advisors's PHAT Position: Q1 2026 in Review

Parallel Advisors held its Phathom Pharmaceuticals (PHAT) position steady in Q1 2026 at 100 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3521.

Parallel Advisors first reported a position in PHAT in Q4 2021 and has held it in 9 quarters since. The position peaked at $2.19K in Q3 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

Parallel Advisors held 100 shares of Phathom Pharmaceuticals worth $1.11K as of Q1 2026.
Parallel Advisors left its Phathom Pharmaceuticals share count unchanged in Q1 2026.
Phathom Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3521 holding.
Parallel Advisors first reported a position in Phathom Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
Parallel Advisors's Phathom Pharmaceuticals position peaked at $2.19K in Q3 2025.
174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.